ProMRI PROVEN Master Study
Launched by BIOTRONIK SE & CO. KG · Mar 12, 2013
Trial Information
Current as of May 30, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Written informed consent
- • Able and willing to complete MRI testing
- • Able and willing to activate and use the Cardio Messenger
- • Able and willing to complete all testing required by the clinical protocol
- • Available for all follow-up visits at the investigational site
- • Standard indication for single, dual, or triple chamber ICD or CRT-P.
- • ICD or CRT-P system to be implanted in the pectoral region
- • Patient body height ≥ 140 cm
- • Age ≥ 18 years
- Exclusion Criteria:
- • Standard contraindication for single, dual, or triple chamber ICD or CRT-P.
- • Systems with an atrial lead: The patient has persistent (lasting longer than 7 days or requiring cardioversion) or permanent atrial arrhythmia
- • Patient has other medical implants that may interact with MRI, e.g. abandoned pacemaker/ICD leads, lead extensions, mechanical valves, other active medical devices, non-MRI compatible devices
- • Patient has other metallic artifacts / components in body that may interact with MRI
- • Life expectancy of less than eight months
- • Cardiac surgery in the next eight months
- • Pregnant or breastfeeding
- • Enrolled in another non-observational cardiac clinical investigation
About Biotronik Se & Co. Kg
Biotronik SE & Co. KG is a global leader in the development of innovative medical technology, specializing in cardiovascular and endovascular solutions. With a strong commitment to enhancing patient outcomes, the company focuses on advanced therapies and devices, including implantable cardioverter-defibrillators, cardiac resynchronization therapy, and vascular interventions. Biotronik's rigorous research and development initiatives, coupled with its dedication to clinical excellence, position the company at the forefront of medical advancement, striving to improve quality of life for patients worldwide. Through strategic partnerships and a robust clinical trial portfolio, Biotronik continues to drive innovation and set new standards in healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Adelaide, , Australia
Montreal, Quebec, Canada
Toronto, Ontario, Canada
Perth, , Australia
Box Hill, Victoria, Australia
Toronto, Ontario, Canada
Camperdown, New South Wales, Australia
Bedford Park, South Australia, Australia
Adelaide, , Australia
Würzburg, , Germany
Essen, , Germany
St. Poelten, , Austria
Brest, , France
Bonn, , Germany
Budapest, , Hungary
Coburg, , Germany
Olomouc, , Czech Republic
Linz, , Austria
Zürich, , Switzerland
Edmonton, , Canada
Perth, , Australia
Sydney, , Australia
Sherbrooke, Quebec, Canada
Tours, , France
Villingen Schwenningen, , Germany
Patients applied
Trial Officials
Wolfgang R. Bauer, Prof.Dr.Dr.
Principal Investigator
Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik I, Oberdürrbacher Str. 6, 97080 Würzburg, Germany
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials